UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/763,972	01/23/2004	Mark David Fidock	PC10960B	8280

28523 7590 11/30/2004

PFIZER INC.
PATENT DEPARTMENT, MS8260-1611
EASTERN POINT ROAD
GROTON, CT 06340

EXAMINER	
LI, RUIXIANG	
ART UNIT	**PAPER NUMBER**
1646	

DATE MAILED: 11/30/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/763,972	FIDOCK, MARK DAVID	
	Examiner	Art Unit	
	Ruixiang Li	1646	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *17 September 2004*.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1 and 4-20* is/are pending in the application.

4a) Of the above claim(s) *9 and 11-20* is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *1,4-8 and 10* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☒ The drawing(s) filed on *23 January 2004* is/are: a)☒ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☒ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☒ Certified copies of the priority documents have been received in Application No. 10/023,586.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date *09/17/2004*.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☒ Other: *Sequence alignment*.

DETAILED ACTION

Election/Restrictions

1. Applicant's election with traverse of Group I, claims 1-8 and 10, in the reply filed on September 17, 2004 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).
2. Applicants' preliminary amendment filed on September 17, 2004 has been entered. Claims 2 and 3 have been canceled. Claims 1, 4, and 10 have been amended. Claims 1 and 4-20 pending. Claims 1, 4-8, and 10 are under consideration. All other claims are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

Priority

3. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. 119(e) to provisional applications 60/260,563 (filed on 01/09/2001) and 60/265,688 (filed on 02/01/2001).

Acknowledgment is also made of applicant's claim for foreign priority under 35 U.S.C. 119(a)-(d). Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been received in application 10/023,586

Drawings

4. The drawings filed on 01/23/2004 are accepted by the Examiner.

Information Disclosure Statement

5. The information disclosure statement filed on 09/17/2004 has been considered by the Examiner and a signed copy of the form PTO-1449 is attached to the office action.

Rejections—35 USC § 101

6. 35 U.S.C. 101 reads as follows:

> Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

7. Claims 1, 4-8, and 10 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well-established utility.

Claims 1, 4-8, and 10 are drawn to an isolated polynucleotide, a vector, a host cell, and a method of producing a polypeptide encoded by the polynucleotide. The claimed invention is not supported by either a specific and substantial asserted utility or a well-established utility. A specific and substantial utility is one that is particular to the subject matter claimed and that identifies a "real world" context of use for the claimed invention which does not requires further research.

The invention is based upon the discovery of PFI-020 nucleic acid sequence by bioinformatics analysis. The specification asserts that PFI-020 nucleic acid sequence encodes a encoding a G-protein coupled receptor whose ligand is likely to

be a nucleotide or a nucleotide derivative and that the PFI-020 polypeptide is most similar to purinergic receptors and (page 16). The specification further discloses PFI-020 polypeptide activation by various purinoceptor agonists in a FLIPR cell-based assay (Example 5; Figures 3-6). Nonetheless, the specification fails to disclose the specific biological functions or any physiological significance of the PFI-020 and fails to disclose a specific and substantial utility for the claimed invention. Thus, one skilled in the art would not be able to recognize the use of the claimed invention in its currently available form and to know what to do with the claimed nucleic acids.

The specification asserts that the present invention provides agonists and antagonists of the polypeptides of the present invention, which are useful in treatment of a list of numerous diseases (pages 6-7 of specification). However, these asserted utilities are not specific and substantial because they do not identify or reasonably confirm a "real world" context of use. The specification neither identifies the biological functions of the polypeptides or nucleic acids of the present invention nor any diseases that are associated with the molecules of the present invention. Clearly, further research would be required to determine the functions of the claimed molecules or to identify a disease that can be treated or diagnosed with the claimed molecules See *Brenner v. Manson*, 383 U.S. 519, 148 USPQ 689 (Sup. Ct. 1966), noting that "a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion."

The specification further asserts the utilities of polynucleotides as primers or hybridization probes (page 12, last paragraph). However, such uses are all

considered research uses only designed to identify a particular function of the claimed molecules and are not a substantial utility. See, e.g., *Brenner v. Manson*, 383 U.S. 519, 148 USPQ 689 (Sup. Ct. 1966) wherein a research utility was not considered a "substantial utility." Moreover, such uses are not specific to the instant molecule but applicable to any nucleic acid molecules.

The invention also lacks a well-established utility. A well-established utility is a specific, substantial, and creditable utility that is well known, immediately apparent, or implied by the specification's disclosure of the properties of a material. The sequence homology of the amino acid sequence of PFI-020 with the purinergic receptors (Fig. 2 and page 16) does not endow the claimed nucleic acids with a specific and substantial utility because members of purinergic receptors have diverse structures and biological functions (see, e.g., Harden et al, Annu. Rev. Pharmacol. Toxicol. 35: 541-579, 1995; Bhagwat et al, Eur. J. Med. Chem. 32:183-193, 1997) and the functions of each receptor need to be determined individually. Even the specification acknowledges that there are several diverse families of receptors, which respond to purine and pyrimidines (4th paragraph of page 2). No art of record discloses or suggests any property or activity for the claimed molecules such that another non-asserted utility would be well-established for the compounds.

8. Claims 1, 4-8, and 10 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Claim Rejections—35 USC § 112, 2nd paragraph

9. The following is a quotation of the second paragraph of 35 U.S.C. 112:

> The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

10. Claims 7 and 10 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 7 is indefinite because it is unclear what protein is to be made; the claim, as written, reads on any proteins produced by the cell.

Claim 10 is indefinite because it recites "a membrane preparation of the cells". It is unclear whether applicants intend to claim a preparation of the polypeptide of SEQ ID NO: 2 or a membrane preparation that does not necessarily comprise the polypeptide of SEQ ID NO: 2. For example, in E. coli cells, the majority of the polypeptide would be present in inclusion bodies.

Claim Rejections—35 USC § 102

11. The following is a quotation of the appropriate paragraphs of 35 U.S.C. §102 that form the basis for the rejections under this section made in this Office action:

> A person shall be entitled to a patent unless –
>
> (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

12. Claims 1, 4-8, and 10 are rejected under 35 U.S.C. §102(e) as being anticipated by Ramakrishnan (WO200185764-A2, pub. Date: November 15, 2001; filing date: May 9, 2001; earlist 102 (e) date: May 11, 2000).

Ramakrishnan teaches an isolated polynucleotide that encodes the amino acid sequence of SEQ ID NO: 2 (see attached sequence alignment). Ramakrishnan also teaches a nucleic acid vector comprising the nucleic acid molecule, a host cell (including mammalian cells; page 23) containing the vector, and a method for producing a polypeptide. Ramakrishnan further teaches membrane preparation of the cells (page 72, line 5; page 75, line 19). Therefore, the reference of Ramakrishnan meets the limitations of claims 1, 4-8, and 10.

Conclusion

13. No claims are allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback, can be reached on (571) 272-0961. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, please contact the Electronic Business Center (EBC) at the toll-free phone number 866-217-9197.

Ruixiang Li

Ruixiang Li, Ph.D.
Examiner
November 29, 2004

CC The invention relates to a novel polynucleotide encoding a guanosine
CC triphosphate-binding protein coupled receptor (GPCR). A polynucleotide of
CC the invention may have a use in gene therapy. The polynucleotide and
CC polypeptide are useful for preparing a composition for treating a patient
CC in need of increased or suppressed activity or expression of the
CC guanosine triphosphate-binding protein coupled receptor. The
CC polynucleotide sequences shown in ADC85548-ADC87616 encode GPCR's of the
CC invention.
XX
SQ Sequence 1334 BP; 283 A; 368 C; 348 G; 335 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.48e-176	Length:	1334
Score:	1936.00	Matches:	360
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	10	Gaps:	0

US-10-763-972-2 (1-360) x ADC86166 (1-1334)

```
Qy          1 MetLeuSerIleLeuLeuProSerArgGlySerArgSerGlySerArgArgGlyAlaLeu 20
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        117 ATGCTGTCCATTTTGCTTCCTTCCAGGGGAAGCAGAAGCGGGAGCCGTCGTGGAGCTCTG 176

Qy         21 LeuLeuGluGlyAlaSerArgAspMetGluLysValAspMetAsnThrSerGlnGluGln 40
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        177 CTCCTGGAGGGAGCCTCCCGGGACATGGAGAAGGTGGACATGAATACATCACAGGAACAA 236

Qy         41 GlyLeuCysGlnPheSerGluLysTyrLysGlnValTyrLeuSerLeuAlaTyrSerIle 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        237 GGTCTCTGCCAGTTCTCAGAGAAGTACAAGCAAGTCTACCTCTCCCTGGCCTACAGTATC 296

Qy         61 IlePheIleLeuGlyLeuProLeuAsnGlyThrValLeuTrpHisSerTrpGlyGlnThr 80
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        297 ATCTTTATCCTAGGGCTGCCAGTAAATGGCACTGTCTTGTGGCACTCCTGGGGCCAAACC 356

Qy         81 LysArgTrpSerCysAlaThrThrTyrLeuValAsnLeuMetValAlaAspLeuLeuTyr 100
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        357 AAGCGCTGGAGCTGTGCCACCACCTATCTGGTGAACCTGATGGTGGCCGACCTGCTTTAT 416

Qy        101 ValLeuLeuProPheLeuIleIleThrTyrSerLeuAspAspArgTrpProPheGlyGlu 120
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        417 GTGCTATTGCCCTTCCTCATCATCACCTACTCACTAGATGACAGGTGGCCCTTCGGGGAG 476

Qy        121 LeuLeuCysLysLeuValHisPheLeuPheTyrIleAsnLeuTyrGlySerIleLeuLeu 140
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        477 CTGCTCTGCAAGCTGGTGCACTTCCTGTTCTATATCAACCTTTACGGCAGCATCCTGCTG 536

Qy        141 LeuThrCysIleSerValHisGlnPheLeuGlyValCysHisProLeuCysSerLeuPro 160
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        537 CTGACCTGCATCTCTGTGCACCAGTTCCTAGGTGTGTGCCACCCACTGTGTTCGCTGCCC 596

Qy        161 TyrArgThrArgArgHisAlaTrpLeuGlyThrSerThrThrTrpAlaLeuValValLeu 180
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        597 TACCGGACCCGCAGGCATGCCTGGCTGGGCACCAGCACCACCTGGGCCCTGGTGGTCCTC 656

Qy        181 GlnLeuLeuProThrLeuAlaPheSerHisThrAspTyrIleAsnGlyGlnMetIleTrp 200
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        657 CAGCTGCTGCCCACACTGGCCTTCTCCCACACGGACTACATCAATGGCCAGATGATCTGG 716

Qy        201 TyrAspMetThrSerGlnGluAsnPheAspArgLeuPheAlaTyrGlyIleValLeuThr 220
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        717 TATGACATGACCAGCCAAGAGAATTTTGATCGGCTTTTTGCCTACGGCATAGTTCTGACA 776

Qy        221 LeuSerGlyPheLeuSerLeuLeuGlyHisPheGlyValLeuPheThrAspGlyGlnGlu 240
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        777 TTGTCTGGCTTTCTTTCCCTCCTTGGTCATTTTGGTGTGCTATTCACTGATGGTCAGGAG 836

Qy        241 ProAspGlnAlaArgGlyGluProHisGluAspArgGlnHisSerProSerGlnValHis 260
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        837 CCTGATCAAGCCAGAGGAGAACCTCATGAGGACAGGCAACACAGCCCGAGCCAGGTCCAT 896

Qy        261 ProAspHisProThrGlyValTrpProLeuHisProLeuPheCysAlaLeuProTyrHis 280
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        897 CCGGACCATCCTACTGGTGTGTGGCCTCTTCACCCTCTGTTTTGTGCCCTTCCATATCAC 956

Qy        281 SerLeuLeuLeuProHisHisLeuLeuSerAlaPheSerGlyLeuProAlaLeuAspGly 300
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        957 TCGCTCCTTCTACCTCACCATCTGCTTTCTGCTTTCTCAGGACTGCCAGCTCTTGATGGC 1016

Qy        301 SerGlnCysGlyLeuGlnAspMetGluAlaSerGlyGluCysGluGlnLeuProGlnPro 320
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1017 AGCCAGTGTGGCCTACAAGATATGGAGGCCTCTGGTGAGTGTGAGCAGCTGCCTCAACCC 1076

Qy        321 SerProValLeuSerPheLysGlyGlyLysAsnArgValArgLeuLeuGlnLysLeuArg 340
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1077 AGTCCTGTACTTTCTTTCAAGGGGGGCAAAAATAGAGTCAGGCTCCTCCAGAAACTGAGG 1136

Qy        341 GlnAsnLysLeuGlyGluHisProAlaGlyArgLysArgCysProGlyLeuAsnArgSer 360
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1137 CAGAACAAGTTGGGTGAGCATCCAGCTGGGAGGAAGAGATGCCCAGGGTTGAACAGATCT 1196
```

RESULT 4
AAS17746
ID AAS17746 standard; DNA; 3143 BP.
XX
AC AAS17746;
XX
DT 26-FEB-2002 (first entry)
XX
DE Human genomic clone for P2Y-like G protein-coupled receptor.
XX
KW Human; ds; P2Y-like G protein-coupled receptor; GPCR; COPD;
KW chronic obstructive pulmonary disease; nervous system disease;
KW Parkinson's disease; multiple sclerosis; dementia; stroke;
KW Alzheimer's disease; benign prostatic hyperplasia; urinary incontinence;
KW bacterial infection; fungal infection; protozoan infection;
KW viral infection; pain; cancer; anorexia; bulimia; asthma;
KW acute heart failure; hypotension; hypertension; osteoporosis; diabetes;
KW angina pectoris; myocardial infarction; ulcer; inflammation; allergy;
KW psychotic disorder; neurological disorder; anxiety; schizophrenia;
KW manic depression; delirium; severe mental retardation; dyskinesia.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 520. .2498
FT /*tag= a
FT /product= "P2Y-like GPCR"
XX
PN WO200185764-A2.
XX
PD 15-NOV-2001.
XX
PF 09-MAY-2001; 2001WO-EP005244.
XX
PR 11-MAY-2000; 2000US-0203582P.
PR 21-FEB-2001; 2001US-0269857P.
XX
PA (FARB) BAYER AG.
XX
PI Ramakrishnan S;
XX
DR WPI; 2002-075242/10.
DR P-PSDB; AAU11251.
XX
PT New polynucleotides for producing P2Y-like G protein-coupled receptors
PT (GPCR) that are used for screening inhibitors or regulators of human P2Y-
PT like GPCR, especially useful for treating pain, cancer or neurological
PT disorders.
XX
PS Disclosure; Fig 1; 114pp; English.
XX
CC The invention relates to an isolated polynucleotide encoding a P2Y-like G
CC protein-coupled receptor (GPCR) polypeptide, its fragment, derivative or

CC allele, a host cell containing an expression vector comprising the
CC polynucleotide and screening for agents that regulate the GPCR activity.
CC The polynucleotide is useful for producing P2Y-like GPCR polypeptide,
CC which may be employed for screening agents that inhibit or regulate human
CC P2Y-like GPCR. The reagent or inhibitor of the human P2Y-like GPCR is
CC useful for treating or ameliorating P2Y-like GPCR disorders, particularly
CC COPD (chronic obstructive pulmonary disease), peripheral or central
CC nervous system disease (e.g. Parkinson's disease, multiple sclerosis,
CC dementia, stroke, Alzheimer's disease and many other diseases and
CC disorders listed in the specification), benign prostatic hyperplasia or
CC urinary incontinence. A pharmaceutical composition containing the
CC modulators and/or regulators of P2Y-like GPCR is useful for modulating
CC the activity of a P2Y-like GPCR. In particular, these are useful for
CC treating, preventing or ameliorating infections (e.g. bacterial, fungal,
CC protozoan or viral infections), pain, cancer, anorexia, bulimia, asthma,
CC acute heart failure, hypotension, hypertension, osteoporosis, diabetes,
CC angina pectoris, myocardial infarction, ulcers, inflammation, allergies,
CC psychotic or neurological disorders (e.g. anxiety, schizophrenia, manic
CC depression, delirium, severe mental retardation or dyskinesias). The
CC present sequence is a genomic clone encoding the P2Y-like GPCR of the
CC invention
XX
SQ Sequence 3143 BP; 818 A; 771 C; 726 G; 828 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	5.07e-176	Length:	3143
Score:	1936.00	Matches:	360
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	6	Gaps:	0

US-10-763-972-2 (1-360) x AAS17746 (1-3143)

```
Qy          1 MetLeuSerIleLeuLeuProSerArgGlySerArgSerGlySerArgArgGlyAlaLeu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        436 ATGCTGTCCATTTTGCTTCCTTCCAGGGGAAGCAGAAGCGGGAGCCGTCGTGGAGCTCTG 495

Qy         21 LeuLeuGluGlyAlaSerArgAspMetGluLysValAspMetAsnThrSerGlnGluGln 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        496 CTCCTGGAGGGAGCCTCCCGGGACATGGAGAAGGTGGACATGAATACATCACAGGAACAA 555

Qy         41 GlyLeuCysGlnPheSerGluLysTyrLysGlnValTyrLeuSerLeuAlaTyrSerIle 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        556 GGTCTCTGCCAGTTCTCAGAGAAGTACAAGCAAGTCTACCTCTCCCTGGCCTACAGTATC 615

Qy         61 IlePheIleLeuGlyLeuProLeuAsnGlyThrValLeuTrpHisSerTrpGlyGlnThr 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        616 ATCTTTATCCTAGGGCTGCCACTAAATGGCACTGTCTTGTGGCACTCCTGGGGCCAAACC 675

Qy         81 LysArgTrpSerCysAlaThrThrTyrLeuValAsnLeuMetValAlaAspLeuLeuTyr 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        676 AAGCGCTGGAGCTGTGCCACCACCTATCTGGTGAACCTGATGGTGGCCGACCTGCTTTAT 735

Qy        101 ValLeuLeuProPheLeuIleIleThrTyrSerLeuAspAspArgTrpProPheGlyGlu 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        736 GTGCTATTGCCCTTCCTCATCATCACCTACTCACTAGATGACAGGTGGCCCTTCGGGGAG 795

Qy        121 LeuLeuCysLysLeuValHisPheLeuPheTyrIleAsnLeuTyrGlySerIleLeuLeu 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        796 CTGCTCTGCAAGCTGGTGCACTTCCTGTTCTATATCAACCTTTACGGCAGCATCCTGCTG 855

Qy        141 LeuThrCysIleSerValHisGlnPheLeuGlyValCysHisProLeuCysSerLeuPro 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        856 CTGACCTGCATCTCTGTGCACCAGTTCCTAGGTGTGTGCCACCCACTGTGTTCGCTGCCC 915

Qy        161 TyrArgThrArgArgHisAlaTrpLeuGlyThrSerThrThrTrpAlaLeuValValLeu 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        916 TACCGGACCCGCAGGCATGCCTGGCTGGGCACCAGCACCACCTGGGCCCTGGTGGTCCTC 975

Qy        181 GlnLeuLeuProThrLeuAlaPheSerHisThrAspTyrIleAsnGlyGlnMetIleTrp 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        976 CAGCTGCTGCCCACACTGGCCTTCTCCCACACGGACTACATCAATGGCCAGATGATCTGG 1035

Qy        201 TyrAspMetThrSerGlnGluAsnPheAspArgLeuPheAlaTyrGlyIleValLeuThr 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1036 TATGACATGACCAGCCAAGAGAATTTTGATCGGCTTTTTGCCTACGGCATAGTTCTGACA 1095

Qy        221 LeuSerGlyPheLeuSerLeuLeuGlyHisPheGlyValLeuPheThrAspGlyGlnGlu 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1096 TTGTCTGGCTTTCTTTCCCTCCTTGGTCATTTTGGTGTGCTATTCACTGATGGTCAGGAG 1155

Qy        241 ProAspGlnAlaArgGlyGluProHisGluAspArgGlnHisSerProSerGlnValHis 260
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1156 CCTGATCAAGCCAGAGGAGAACCTCATGAGGACAGGCAACACAGCCCGAGCCAGGTCCAT 1215

Qy        261 ProAspHisProThrGlyValTrpProLeuHisProLeuPheCysAlaLeuProTyrHis 280
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1216 CCGGACCATCCTACTGGTGTGTGGCCTCTTCACCCTCTGTTTTGTGCCCTTCCATATCAC 1275

Qy        281 SerLeuLeuLeuProHisHisLeuLeuSerAlaPheSerGlyLeuProAlaLeuAspGly 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1276 TCGCTCCTTCTACCTCACCATCTGCTTTCTGCTTTCTCAGGACTGCCAGCTCTTGATGGC 1335

Qy        301 SerGlnCysGlyLeuGlnAspMetGluAlaSerGlyGluCysGluGlnLeuProGlnPro 320
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1336 AGCCAGTGTGGCCTACAAGATATGGAGGCCTCTGGTGAGTGTGAGCAGCTGCCTCAACCC 1395

Qy        321 SerProValLeuSerPheLysGlyGlyLysAsnArgValArgLeuLeuGlnLysLeuArg 340
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1396 AGTCCTGTACTTTCTTTCAAGGGGGGCAAAAATAGAGTCAGGCTCCTCCAGAAACTGAGG 1455

Qy        341 GlnAsnLysLeuGlyGluHisProAlaGlyArgLysArgCysProGlyLeuAsnArgSer 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1456 CAGAACAAGTTGGGTGAGCATCCAGCTGGGAGGAAGAGATGCCCAGGGTTGAACAGATCT 1515
```

RESULT 5
AAS98135
ID AAS98135 standard; DNA; 1063 BP.
XX
AC AAS98135;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human DNA for potential G protein-coupled receptor #92.
XX
KW Human; G protein-coupled receptor; GPCR; ds; GAL4; galanin receptor;
KW Alzheimer's disease; amyotrophic lateral sclerosis; asthma;
KW atherosclerosis; basal cell carcinoma; breast carcinoma; cardiomyopathy;
KW chondrosarcoma; chronic obstructive pulmonary disease; Crohn's disease;
KW depression; epilepsy; macular degeneration; lymphoma; melanoma;
KW multiple sclerosis; osteoarthritis; osteoporosis; Parkinson's disease;
KW psoriasis; rheumatoid arthritis; schizophrenia; ulcerative colitis;
KW tuberculosis; cognition disorder; memory disorder; anorexia;
KW hormonal release disorder; cardiovascular activity disorder;
KW pain perception disorder; obesity; diabetes; obesity; diabetes;
KW hyperlipidaemia; stroke; gene therapy.
XX
OS Homo sapiens.
XX
PN WO200185791-A1.
XX
PD 15-NOV-2001.
XX
PF 11-MAY-2001; 2001WO-US015312.
XX
PR 11-MAY-2000; 2000US-0203217P.
PR 18-MAY-2000; 2000US-0205945P.
XX
PA (LIFE-) LIFESPAN BIOSCIENCES INC.
XX
PI Brown JP, Miller M, Burmer G, Fabre-Suver C, Pritchard D;
XX
DR WPI; 2002-066595/09.
XX
PT Novel G protein-coupled receptor polypeptides including galanin receptor



```
Db        117 ATGCTGTCCATTTTGCTTCCTTCCAGGGGAAGCAGAAGCGGGAGCCGTCGTGGAGCTCTG 176
Qy         61 CTCCTGGAGGGAGCCTCCCCGGGACATGGAGAAGGTGGACATGAATACATCACAGGAACAA 120
Db        177 CTCCTGGAGGGAGCCTCCCGGGACATGGAGAAGGTGGACATGAATACATCACAGGAACAA 236
Qy        121 GGTCTCTGCCAGTTCTCAGAGAAGTACAAGCAAGTCTACCTCTCCCTGGCCTACAGTATC 180
Db        237 GGTCTCTGCCAGTTCTCAGAGAAGTACAAGCAAGTCTACCTCTCCCTGGCCTACAGTATC 296
Qy        181 ATCTTTATCCTAGGGCTGCCACTAAATGGCACTGTCTTGTGGCACTCCTGGGGCCAAACC 240
Db        297 ATCTTTATCCTAGGGCTGCCACTAAATGGCACTGTCTTGTGGCACTCCTGGGGCCAAACC 356
Qy        241 AAGCGCTGGAGCTGTGCCACCACCTATCTGGTGAACCTGATGGTGGCCGACCTGCTTTAT 300
Db        357 AAGCGCTGGAGCTGTGCCACCACCTATCTGGTGAACCTGATGGTGGCCGACCTGCTTTAT 416
Qy        301 GTGCTATTGCCCTTCCTCATCATCACCTACTCACTAGATGACAGGTGGCCCTTCGGGGAG 360
Db        417 GTGCTATTGCCCTTCCTCATCATCACCTACTCACTAGATGACAGGTGGCCCTTCGGGGAG 476
Qy        361 CTGCTCTGCAAGCTGGTGCACTTCCTGTTCTATATCAACCTTTACGGCAGCATCCTGCTG 420
Db        477 CTGCTCTGCAAGCTGGTGCACTTCCTGTTCTATATCAACCTTTACGGCAGCATCCTGCTG 536
Qy        421 CTGACCTGCATCTCTGTGCACCAGTTCCTAGGTGTGTGCCACCCACTGTGTTCGCTGCCC 480
Db        537 CTGACCTGCATCTCTGTGCACCAGTTCCTAGGTGTGTGCCACCCACTGTGTTCGCTGCCC 596
Qy        481 TACCGGACCCGCAGGCATGCCTGGCTGGGCACCAGCACCACCTGGGCCCTGGTGGTCCTC 540
Db        597 TACCGGACCCGCAGGCATGCCTGGCTGGGCACCAGCACCACCTGGGCCCTGGTGGTCCTC 656
Qy        541 CAGCTGCTGCCCACACTGGGCTTCTCCCACACGGACTACATCAATGGCCAGATGATCTGG 600
Db        657 CAGCTGCTGCCCACACTGGCCTTCTCCCACACGGACTACATCAATGGCCAGATGATCTGG 716
Qy        601 TATGACATGACCAGCCAAGAGAATTTTGATCGGCTTTTTGCCTACGGCATAGTTCTGACA 660
Db        717 TATGACATGACCAGCCAAGAGAATTTTGATCGGCTTTTTGCCTACGGCATAGTTCTGACA 776
Qy        661 TTGTCTGGCTTTCTTTCCCTCCTTGGTGATTTTGGTGTGCTATTCACTGATGGTCAGGAG 720
Db        777 TTGTCTGGCTTTCTTTCCCTCCTTGGTCATTTTGGTGTGCTATTCACTGATGGTCAGGAG 836
Qy        721 CCTGATCAAGCCAGAGGAGAACCTCATGAGGACAGGCAACACAGCCCGAGCCAGGTCCAT 780
Db        837 CCTGATCAAGCCAGAGGAGAACCTCATGAGGACAGGCAACACAGCCCGAGCCAGGTCCAT 896
Qy        781 CCGGACCATCCTACTGGTGTGTGGCCTCTTCACCCTCTGTTTTGTGCCCTTCCATATCAC 840
Db        897 CCGGACCATCCTACTGGTGTGTGGCCTCTTCACCCTCTGTTTTGTGCCCTTCCATATCAC 956
Qy        841 TCGCTCCTTCTACCTCACCATCTGCTTTCTGCTTTCTCAGGACTGCCAGCTCTTGATGGC 900
Db        957 TCGCTCCTTCTACCTCACCATCTGCTTTCTGCTTTCTCAGGACTGCCAGCTCTTGATGGC 1016
Qy        901 AGCCAGTGTGGCCTACAAGATATGGAGGCCTCTGGTGAGTGTGAGCAGCTGCCTCAACCC 960
Db       1017 AGCCAGTGTGGCCTACAAGATATGGAGGCCTCTGGTGAGTGTGAGCAGCTGCCTCAACCC 1076
Qy        961 AGTCCTGTACTTTCTTTCAAGGGGGGCAAAAATAGAGTCAGGCTCCTCCAGAAACTGAGG 1020
Db       1077 AGTCCTGTACTTTCTTTCAAGGGGGGCAAAAATAGAGTCAGGCTCCTCCAGAAACTGAGG 1136
Qy       1021 CAGAACAAGTTGGGTGAGCATCCAGCTGGGAGGAAGAGATGCCCAGGGTTGAACAGATCT 1080
Db       1137 CAGAACAAGTTGGGTGAGCATCCAGCTGGGAGGAAGAGATGCCCAGGGTTGAACAGATCT 1196
Qy       1081 GG 1082
Db       1197 GG 1198
```

RESULT 4
AAS17746
ID AAS17746 standard; DNA; 3143 BP.
XX
AC AAS17746;
XX
DT 26-FEB-2002 (first entry)
XX
DE Human genomic clone for P2Y-like G protein-coupled receptor.
XX
KW Human; ds; P2Y-like G protein-coupled receptor; GPCR; COPD;
KW chronic obstructive pulmonary disease; nervous system disease;
KW Parkinson's disease; multiple sclerosis; dementia; stroke;
KW Alzheimer's disease; benign prostatic hyperplasia; urinary incontinence;
KW bacterial infection; fungal infection; protozoan infection;
KW viral infection; pain; cancer; anorexia; bulimia; asthma;
KW acute heart failure; hypotension; hypertension; osteoporosis; diabetes;
KW angina pectoris; myocardial infarction; ulcer; inflammation; allergy;
KW psychotic disorder; neurological disorder; anxiety; schizophrenia;
KW manic depression; delirium; severe mental retardation; dyskinesia.
XX
OS Homo sapiens.
XX
FH Key   Location/Qualifiers
FT CDS   520. .2498
FT   /*tag= a
FT   /product= "P2Y-like GPCR"
XX
PN WO200185764-A2.
XX
PD 15-NOV-2001.
XX
PF 09-MAY-2001; 2001WO-EP005244.
XX
PR 11-MAY-2000; 2000US-0203582P.
PR 21-FEB-2001; 2001US-0269857P.
XX
PA (FARB) BAYER AG.
XX
PI Ramakrishnan S;
XX
DR WPI; 2002-075242/10.
DR P-PSDB; AAU11251.
XX
PT New polynucleotides for producing P2Y-like G protein-coupled receptors
PT (GPCR) that are used for screening inhibitors or regulators of human P2Y-
PT like GPCR, especially useful for treating pain, cancer or neurological
PT disorders.
XX
PS Disclosure; Fig 1; 114pp; English.
XX
CC The invention relates to an isolated polynucleotide encoding a P2Y-like G
CC protein-coupled receptor (GPCR) polypeptide, its fragment, derivative or
CC allele, a host cell containing an expression vector comprising the
CC polynucleotide and screening for agents that regulate the GPCR activity.
CC The polynucleotide is useful for producing P2Y-like GPCR polypeptide,
CC which may be employed for screening agents that inhibit or regulate human
CC P2Y-like GPCR. The reagent or inhibitor of the human P2Y-like GPCR is
CC useful for treating or ameliorating P2Y-like GPCR disorders, particularly
CC COPD (chronic obstructive pulmonary disease), peripheral or central
CC nervous system disease (e.g. Parkinson's disease, multiple sclerosis,
CC dementia, stroke, Alzheimer's disease and many other diseases and
CC disorders listed in the specification), benign prostatic hyperplasia or
CC urinary incontinence. A pharmaceutical composition containing the
CC modulators and/or regulators of P2Y-like GPCR is useful for modulating
CC the activity of a P2Y-like GPCR. In particular, these are useful for
CC treating, preventing or ameliorating infections (e.g. bacterial, fungal,
CC protozoan or viral infections), pain, cancer, anorexia, bulimia, asthma,
CC acute heart failure, hypotension, hypertension, osteoporosis, diabetes,
CC angina pectoris, myocardial infarction, ulcers, inflammation, allergies,

```
CC   psychotic or neurological disorders (e.g. anxiety, schizophrenia, manic
CC   depression, delirium, severe mental retardation or dyskinesias). The
CC   present sequence is a genomic clone encoding the P2Y-like GPCR of the
CC   invention
XX
SQ   Sequence 3143 BP; 818 A; 771 C; 726 G; 828 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 1082;  DB 6;  Length 3143;
  Best Local Similarity   100.0%;  Pred. No. 6.4e-285;
  Matches 1082;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ATGCTGTCCATTTTGCTTCCTTCCAGGGGAAGCAGAAGCGGGAGCCGTCGTGGAGCTCTG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        436 ATGCTGTCCATTTTGCTTCCTTCCAGGGGAAGCAGAAGCGGGAGCCGTCGTGGAGCTCTG 495

Qy         61 CTCCTGGAGGGAGCCTCCCGGGACATGGAGAAGGTGGACATGAATACATCACAGGAACAA 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        496 CTCCTGGAGGGAGCCTCCCGGGACATGGAGAAGGTGGACATGAATACATCACAGGAACAA 555

Qy        121 GGTCTCTGCCAGTTCTCAGAGAAGTACAAGCAAGTCTACCTCTCCCTGGCCTACAGTATC 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        556 GGTCTCTGCCAGTTCTCAGAGAAGTACAAGCAAGTCTACCTCTCCCTGGCCTACAGTATC 615

Qy        181 ATCTTTATCCTAGGGCTGCCACTAAATGGCACTGTCTTGTGGCACTCCTGGGGCCAAACC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        616 ATCTTTATCCTAGGGCTGCCACTAAATGGCACTGTCTTGTGGCACTCCTGGGGCCAAACC 675

Qy        241 AAGCGCTGGAGCTGTGCCACCACCTATCTGGTGAACCTGATGGTGGCCGACCTGCTTTAT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        676 AAGCGCTGGAGCTGTGCCACCACCTATCTGGTGAACCTGATGGTGGCCGACCTGCTTTAT 735

Qy        301 GTGCTATTGCCCTTCCTCATCATCACCTACTCACTAGATGACAGGTGGCCCTTCGGGGAG 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        736 GTGCTATTGCCCTTCCTCATCATCACCTACTCACTAGATGACAGGTGGCCCTTCGGGGAG 795

Qy        361 CTGCTCTGCAAGCTGGTGCACTTCCTGTTCTATATCAACCTTTACGGCAGCATCCTGCTG 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        796 CTGCTCTGCAAGCTGGTGCACTTCCTGTTCTATATCAACCTTTACGGCAGCATCCTGCTG 855

Qy        421 CTGACCTGCATCTCTGTGCACCAGTTCCTAGGTGTGTGCCACCCACTGTGTTCGCTGCCC 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        856 CTGACCTGCATCTCTGTGCACCAGTTCCTAGGTGTGTGCCACCCACTGTGTTCGCTGCCC 915

Qy        481 TACCGGACCCGCAGGCATGCCTGGCTGGGCACCAGCACCACCTGGGCCCTGGTGGTCCTC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        916 TACCGGACCCGCAGGCATGCCTGGCTGGGCACCAGCACCACCTGGGCCCTGGTGGTCCTC 975

Qy        541 CAGCTGCTGCCCACACTGGCCTTCTCCCACACGGACTACATCAATGGCCAGATGATCTGG 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        976 CAGCTGCTGCCCACACTGGCCTTCTCCCACACGGACTACATCAATGGCCAGATGATCTGG 1035

Qy        601 TATGACATGACCAGCCAAGAGAATTTTGATCGGCTTTTTGCCTACGGCATAGTTCTGACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1036 TATGACATGACCAGCCAAGAGAATTTTGATCGGCTTTTTGCCTACGGCATAGTTCTGACA 1095

Qy        661 TTGTCTGGCTTTCTTTCCCTCCTTGGTCATTTTGGTGTGCTATTCACTGATGGTCAGGAG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1096 TTGTCTGGCTTTCTTTCCCTCCTTGGTCATTTTGGTGTGCTATTCACTGATGGTCAGGAG 1155

Qy        721 CCTGATCAAGCCAGAGGAGAACCTCATGAGGACAGGCAACACAGCCCGAGCCAGGTCCAT 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1156 CCTGATCAAGCCAGAGGAGAACCTCATGAGGACAGGCAACACAGCCCGAGCCAGGTCCAT 1215

Qy        781 CCGGACCATCCTACTGGTGTGTGGCCTCTTCACCCTCTGTTTTGTGCCCTTCCATATCAC 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1216 CCGGACCATCCTACTGGTGTGTGGCCTCTTCACCCTCTGTTTTGTGCCCTTCCATATCAC 1275

Qy        841 TCGCTCCTTCTACCTCACCATCTGCTTTCTGCTTTCTCAGGACTGCCAGCTCTTGATGGC 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1276 TCGCTCCTTCTACCTCACCATCTGCTTTCTGCTTTCTCAGGACTGCCAGCTCTTGATGGC 1335

Qy        901 AGCCAGTGTGGCCTACAAGATATGGAGGCCTCTGGTGAGTGTGAGCAGCTGCCTCAACCC 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Db       1336 AGCCAGTGTGGCCTACAAGATATGGAGGCCTCTGGTGAGTGTGAGCAGCTGCCTCAACCC 1395

Qy        961 AGTCCTGTACTTTCTTTCAAGGGGGGCAAAAATAGAGTCAGGCTCCTCCAGAAACTGAGG 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1396 AGTCCTGTACTTTCTTTCAAGGGGGGCAAAAATAGAGTCAGGCTCCTCCAGAAACTGAGG 1455

Qy       1021 CAGAACAAGTTGGGTGAGCATCCAGCTGGGAGGAAGAGATGCCCAGGGTTGAACAGATCT 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1456 CAGAACAAGTTGGGTGAGCATCCAGCTGGGAGGAAGAGATGCCCAGGGTTGAACAGATCT 1515

Qy       1081 GG 1082
              ||
Db       1516 GG 1517
```

RESULT 5
ADI16629

```
ID   ADI16629 standard; cDNA; 1108 BP.
XX
AC   ADI16629;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human NOVX cDNA to treat human pathological conditions SeqID165.
XX
KW   gene; ss; human; NOVX; cardiomyopathy; atherosclerosis; cancer; diabetes;
KW   inflammation; autoimmune disorder; allergy; blood disorder;
KW   acquired immunodeficiency syndrome; AIDS; obesity; asthma;
KW   immunoglobulin (Ig)A nephropathy; cirrhosis; arthritis;
KW   Alzheimer's disease; infection; stroke; muscular dystrophy; epilepsy;
KW   cytostatic; cardiant; antiinflammatory; immunosuppressive; antiallergic;
KW   haemostatic; anti-HIV; antidiabetic; antiarteriosclerotic; anorectic;
KW   antiasthmatic; nephrotropic; antiarthritic; hepatotropic;
KW   neuroprotective; nootropic; antibacterial; virucide; antiparasitic;
KW   relaxant; anticonvulsant; neurogenesis; wound healing; angiogenesis;
KW   chromosome mapping; tissue typing; pharmacogenomic;
KW   single nucleotide polymorphism; SNP.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   variation       replace(378,A)
FT                   /*tag=  a
FT                   /standard_name= "Single nucleotide polymorphism"
FT   variation       replace(496,A)
FT                   /*tag=  b
FT                   /standard_name= "Single nucleotide polymorphism"
XX
PN   WO200268649-A2.
XX
PD   06-SEP-2002.
XX
PF   31-JAN-2002; 2002WO-US002785.
XX
PR   31-JAN-2001; 2001US-0265195P.
PR   31-JAN-2001; 2001US-0265412P.
PR   31-JAN-2001; 2001US-0265514P.
PR   31-JAN-2001; 2001US-0265517P.
PR   02-FEB-2001; 2001US-0266406P.
PR   05-FEB-2001; 2001US-0266767P.
PR   07-FEB-2001; 2001US-0266975P.
PR   07-FEB-2001; 2001US-0267057P.
PR   08-FEB-2001; 2001US-0267459P.
PR   09-FEB-2001; 2001US-0267823P.
PR   15-FEB-2001; 2001US-0268974P.
PR   26-FEB-2001; 2001US-0271664P.
PR   27-FEB-2001; 2001US-0271839P.
PR   27-FEB-2001; 2001US-0271855P.
PR   02-MAR-2001; 2001US-0272788P.
PR   02-MAR-2001; 2001US-0273046P.
PR   14-MAR-2001; 2001US-0275925P.
PR   14-MAR-2001; 2001US-0275947P.
PR   14-MAR-2001; 2001US-0275950P.
```